These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients. Duni A; Markopoulos GS; Mallioras I; Pappas H; Pappas E; Koutlas V; Tzalavra E; Baxevanos G; Priska S; Gartzonika K; Mitsis M; Dounousi E Front Immunol; 2021; 12():760249. PubMed ID: 34925330 [TBL] [Abstract][Full Text] [Related]
30. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients. Wu X; Wang L; Shen L; He L; Tang K J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431 [TBL] [Abstract][Full Text] [Related]
31. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G Front Immunol; 2022; 13():863554. PubMed ID: 35711445 [TBL] [Abstract][Full Text] [Related]
32. Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients. Bajwa HM; Novak F; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Witt AH; Byg KE; Johansen IS; Mittl K; Rowles W; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T Mult Scler Relat Disord; 2022 Apr; 60():103729. PubMed ID: 35334278 [TBL] [Abstract][Full Text] [Related]
33. Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients. Cuffel A; Maylin S; Le Buanec H; Delaugerre C; Minier M; Bergerat D; Merandet M; Cassius C; Peffault de Latour R; Le Goff J; Socié G; Caillat-Zucman S; Robin M; Xhaard A Vaccine; 2022 Aug; 40(33):4682-4685. PubMed ID: 35840470 [TBL] [Abstract][Full Text] [Related]
34. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D Front Immunol; 2022; 13():846753. PubMed ID: 35309297 [TBL] [Abstract][Full Text] [Related]
35. Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency. Goda V; Kriván G; Kulcsár A; Gönczi M; Tasnády S; Matula Z; Nagy G; Bekő G; Horváth M; Uher F; Szekanecz Z; Vályi-Nagy I Front Immunol; 2022; 13():907125. PubMed ID: 35784359 [TBL] [Abstract][Full Text] [Related]
37. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy. Jedicke N; Stankov MV; Cossmann A; Dopfer-Jablonka A; Knuth C; Ahrenstorf G; Ramos GM; Behrens GMN HIV Med; 2022 May; 23(5):558-563. PubMed ID: 34725907 [TBL] [Abstract][Full Text] [Related]
38. COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5-11 Years Old-Non-Randomized Clinical Trial. Matkowska-Kocjan A; Owoc-Lempach J; Ludwikowska K; Szenborn F; Moskwa N; Kurek K; Kałwak K; Szenborn L; Ussowicz M Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36680039 [TBL] [Abstract][Full Text] [Related]
39. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
40. Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients. Zhang R; Shin BH; Gadsden TM; Petrosyan A; Vo A; Ammerman N; Sethi S; Huang E; Peng A; Najjar R; Atienza J; Kim I; Jordan SC Transpl Infect Dis; 2022 Apr; 24(2):e13813. PubMed ID: 35202497 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]